Evidence Hub

Antimicrobial peptides RI8 and RW8 target bacterial membranes and genomic DNA to overcome drug resistance

Gao Z, Zhang MY, Cheng YL, Shi YF, Shan XL, Zhang ZX, Han YL, Li S

Bioorganic chemistry, 2026

Abstract

The global rise of multidrug-resistant (MDR) pathogens invalidates conventional antibiotics, while natural antimicrobial peptides (AMPs) lack proteolytic stability and precise targeting. This study reports a protease-resistant symmetric (RRYY)2P(YYRR)2 scaffold (Y = isoleucine/tryptophan) with alternating cationic-hydrophobic repeats, a central proline hinge, and palindromic topology for dual bacterial membrane-genomic DNA targeting. Two derived peptides, RI8 and RW8, were characterized: RI8 showed broad-spectrum activity against MDR pathogens (MIC: 2-16 μg/mL), high therapeutic index (39.4), negligible hemolysis (<1% at 128 μg/mL), and retained efficacy in physiological salts/serum. RW8 exhibited robust protease resistance (1-2× MIC vs trypsin/chymotrypsin, 0.5× MIC vs 8 mg/mL pepsin for 8 h) and Staphylococcus aureus biofilm inhibition (71.4% at 2× MIC) via downregulating icaD/icaB/sarA. Mechanistically, both peptides disrupted bacterial membranes and bound genomic DNA; molecular dynamics simulations confirmed membrane insertion via helix-to-coil transition. In murine models, RI8/RW8 accelerated MDR-infected wound healing and reduced bacterial burdens by 2-5 logs; for S. aureus pneumonia, they outperformed levofloxacin (3-5 vs 2 logs bacterial load reduction) and restored immune function (improved thymus index, reduced pro-inflammatory cytokines). This work establishes a symmetric peptide scaffold as a versatile AMP platform, with RI8 showing promise for systemic MDR…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free